Azenosertib Extends Survival to 15.8 Months in Cyclin E1-Positive Ovarian Cancer
ZNTL sits 89% above its 52-week low of $1.212 on elevated volume (1.8× avg).
Summary
Zentalis said azenosertib produced a median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients versus 7.5 months in the Cyclin E1-negative subgroup, based on a Sept. 2 data cut from DENALI Part 1b. No new safety signals emerged. The company is framing cyclin E1 as a response biomarker, which supports the ongoing DENALI Part 2 and ASPENOVA Phase 3 confirmatory work. This follows the first OS disclosure reported Sunday evening and the August offering that raised $75.1M at $3.50 a share to fund the ovarian program; the stock is up Monday on the data. The abstract precedes a rapid oral presentation at ESMO Congress on Friday, which is the next scheduled public readout.
At the time of this announcement, ZNTL was trading at $2.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $216.3M. The 52-week trading range was $1.21 to $6.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.